BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21756911)

  • 1. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
    Kellner C; Bleeker WK; Lammerts van Bueren JJ; Staudinger M; Klausz K; Derer S; Glorius P; Muskulus A; de Goeij BE; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Aug; 371(1-2):122-33. PubMed ID: 21756911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.
    Klausz K; Kellner C; Derer S; Valerius T; Staudinger M; Burger R; Gramatzki M; Peipp M
    J Immunol Methods; 2015 Mar; 418():75-83. PubMed ID: 25701195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
    Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].
    Grieger E; Gresch G; Niesen J; Woitok M; Barth S; Fischer R; Fendel R; Stein C
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2159-2170. PubMed ID: 28669053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
    Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
    Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model.
    Pardo A; Stöcker M; Kampmeier F; Melmer G; Fischer R; Thepen T; Barth S
    Cancer Immunol Immunother; 2012 Oct; 61(10):1617-26. PubMed ID: 22350071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
    Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
    J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
    Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
    Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
    Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
    Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
    Du X; Ho M; Pastan I
    J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
    Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
    Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant immunotoxins for the treatment of Hodgkin's disease (Review).
    Matthey B; Engert A; Barth S
    Int J Mol Med; 2000 Nov; 6(5):509-14. PubMed ID: 11029515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxins containing Pseudomonas exotoxin A: a short history.
    Pastan I
    Cancer Immunol Immunother; 2003 May; 52(5):338-41. PubMed ID: 12700949
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
    Schmidt M; Wels W
    Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
    Weldon JE; Pastan I
    FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.
    Staudinger M; Glorius P; Burger R; Kellner C; Klausz K; Günther A; Repp R; Klapper W; Gramatzki M; Peipp M
    Blood Cancer J; 2014 Jun; 4(6):e219. PubMed ID: 24927408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
    Barth S; Huhn M; Wels W; Diehl V; Engert A
    Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.
    Schwenkert M; Birkholz K; Schwemmlein M; Kellner C; Kügler M; Peipp M; Nettelbeck DM; Schuler-Thurner B; Schaft N; Dörrie J; Ferrone S; Kämpgen E; Fey GH
    Melanoma Res; 2008 Apr; 18(2):73-84. PubMed ID: 18337643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.